Our daily focus is cost effectively commercializing the life science assets that we have acquired, seeking partnerships for commercialization of assets where appropriate, and identifying new assets that fit well within portfolio and corporate strategy.
In August 2020, we closed our initial exempt offering of unregistered common stock for gross proceeds of approximately $5,562,580.
In July of 2020, we completed the purchase of Somahlution assets in exchange for shares of our common stock.
In December 2019, we entered into an agreement to purchase all of the Somahlution assets, including the DuraGraft product whose technology can be applied to prevent ischemic injury to tissues and organs.
In November 2019, we signed an initial licensing and commercialization agreement with Somahlution LLC, the owner and developer of the DuraGraft product.
On September 12, 2018, we consummated an asset acquisition with ACB Holding AB, a Swedish corporation, and acquired all right, title and interest in the Krillase technology in exchange for 16.98 million unregistered shares of our common stock.
We are a Nevada corporation originally incorporated on March 20, 2007, under the name SWAV Enterprises, Ltd. On September 6, 2010, our name was changed to GBS Enterprises Incorporated, and on March 21, 2018, we changed our name to Marizyme, Inc.